Promising Growth and Strategic Initiatives Justify Buy Rating for Heron Therapeutics
Brandon Folkes has assigned a Buy rating for Heron Therapeutics, citing promising growth driven by their third-quarter earnings report. Key products Zynrelef and Aponvie are entering a critical growth phase, with Zynrelef benefiting from a new permanent J-code that simplifies reimbursement. Year-over-year demand for Zynrelef is strong, supported by strategic initiatives like enhanced distributor incentives. Aponvie's sales growth is bolstered by a dedicated sales team, while stable Cinvanti revenues further indicate a positive outlook for the company.
Brandon Folkes has given his Buy rating due to a combination of factors that highlight the promising future of Heron Therapeutics. The company’s recent third-quarter earnings report indicates positive momentum for their key products, Zynrelef and Aponvie, which are entering a critical phase of commercial growth. The introduction of a permanent J-code for Zynrelef simplifies reimbursement processes, potentially boosting its adoption and sales.
Additionally, Zynrelef’s demand has shown significant year-over-year growth, supported by strategic initiatives such as enhanced distributor incentives and the establishment of a new peri-operative clinical educator team. Aponvie has also demonstrated impressive sales growth, aided by the formation of a dedicated sales team. These developments, along with stable Cinvanti revenues, suggest a strong trajectory for Heron Therapeutics, justifying the Buy rating.
